Hacettepe University Cancer Institute, Ankara, Turkey.
Hacettepe University Cancer Institute, Ankara, Turkey.
Crit Rev Oncol Hematol. 2021 Dec;168:103528. doi: 10.1016/j.critrevonc.2021.103528. Epub 2021 Nov 17.
Pancreatic cancer is a deadly disease with limited therapeutic options. Several strategies are being investigated to improve disease management, including the early diagnosis of recurrences and treatment tailoring by better prognosis estimation. Circulating tumor DNA (ctDNA) could be a promising tool in this regard, although the data is limited. Therefore, we conducted a systemical review and meta-analysis of the published studies on the association of ctDNA and survival outcomes in pancreatic cancer. In the pooled analysis, positive preoperative or postoperative ctDNA was associated with lower RFS/PFS (HR: 2.27, 95 % CI: 1.59-3.24, p < 0.001) and OS (HR: 2.04, 95 % CI: 1.29-3.21, p = 0.002) in localized pancreatic cancer. Similarly, positive baseline ctDNA was associated with lower RFS/PFS (HR: 2.61, 95 % CI: 1.94-3.51, p < 0.001) and OS (HR: 2.41, 95 % CI: 1.74-3.34, p < 0.001) in advanced pancreatic cancer. In conclusion, ctDNA could be a promising tool to individualize treatment planning and to improve outcomes in pancreatic cancer.
胰腺癌是一种致命的疾病，治疗选择有限。目前正在研究几种策略来改善疾病管理，包括通过更好的预后估计来进行复发的早期诊断和治疗调整。循环肿瘤 DNA（ctDNA）在这方面可能是一种很有前途的工具，尽管目前数据有限。因此，我们对已发表的关于 ctDNA 与胰腺癌生存结果相关性的研究进行了系统评价和荟萃分析。在汇总分析中，术前或术后阳性 ctDNA 与局限性胰腺癌的 RFS/PFS（HR：2.27，95%CI：1.59-3.24，p<0.001）和 OS（HR：2.04，95%CI：1.29-3.21，p=0.002）较低相关。同样，基线阳性 ctDNA 与晚期胰腺癌的 RFS/PFS（HR：2.61，95%CI：1.94-3.51，p<0.001）和 OS（HR：2.41，95%CI：1.74-3.34，p<0.001）较低相关。总之，ctDNA 可能是一种很有前途的工具，可以用于个体化治疗计划，并改善胰腺癌的预后。
